Induction-concurrent chemoradiotherapy versus induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma

Surrogate endpoints for overall survival in combined chemotherapy and radiotherapy trials in nasopharyngeal carcinoma: Meta-analysis of randomised controlled trials

“…The trial by Chan et al was first published in 2002 [25] and updated in 2005 [26] with the long-term outcome. The same updates were made to the trials by Lee et al [29,30,32,33], Chen et al [34,35], Huang et al [36,37], and Xu et al [42,43]. The preliminary report of the trial by Chua et al was published in 1998 [20], and the long-term outcome of the majority of patients was reported in 2001 [21]; thus we included the latter publication in our study.…”

Elevated Beclin 1 expression is correlated with HIF-1α in predicting poor prognosis of nasopharyngeal carcinoma

“…The patients of this study originated from a published RCT from September 2003 to April 2005. 53 In this RCT, a strict eligibility criteria protocol was employed as follows: pathologically confirmed as nonkeratinizing or undifferentiated carcinoma of nasopharynx (World Health Organization types of II or III); without radiotherapy, chemotherapy and oncological surgery history; aged 18-65 years (with the median age of 42.5 years); performance status score: 0-2; clinical stage: IIIAs the first identified mammalian autophagy effector, Beclin 1 acts as an obligatory allosteric activator of the class III PtdIns3K in production of PtdIns(3)P. 40 The Beclin 1/class III PtdIns3K complex is essential for autophagosome formation, sorting of autophagosomal components to the phagophore assembly site, and for lysosomal enzyme transport. 18 In light of its central role in autophagy, Beclin 1 had been suggested as a therapeutic molecular target.…”

Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Locoregionally Advanced Nasopharyngeal Carcinoma

“…However, the differences of residual tumor rate after 3 months and the survival rate were of no statistical significance (P> 0.05). Huang et al (2009) from Guangzhou Cancer Laboratory randomly divided 408 cases into two groups that are inductive chemotherapy combined with concurrent radiochemotherapy group (IC/CCRT) and inductive chemotherapy combined with radiotherapy group (IC/RT). The results showed that the differences of progressionfree survival rate, locally control rate and control rate of distantly metastasis were of no statistical significance.…”